Illumina Key Executives
This section highlights Illumina's key executives, including their titles and compensation details.
Find Contacts at Illumina
( total contacts)
Illumina Earnings
This section highlights Illumina's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-05-08 | $0.96 | $0.97 |
| Read Transcript | Q4 | 2024 | 2025-02-06 | $0.92 | $0.86 |
| Read Transcript | Q3 | 2024 | 2024-11-04 | $0.88 | $1.14 |
| Read Transcript | Q2 | 2024 | 2024-08-06 | $0.11 | $0.36 |
| Read Transcript | Q1 | 2024 | 2024-05-02 | $0.04 | $0.09 |
| Read Transcript | Q4 | 2023 | 2024-02-08 | $0.02 | $0.14 |
| Read Transcript | Q3 | 2023 | 2023-11-09 | $0.13 | $0.33 |
| Read Transcript | Q2 | 2023 | 2023-08-10 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-04-25 | $0.03 | $0.08 |
Financial Statements
Access annual & quarterly financial statements for Illumina, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 29, 2024 | December 31, 2023 | January 01, 2023 | January 02, 2022 | January 03, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.37B | $4.50B | $4.58B | $4.53B | $3.24B |
| Cost of Revenue | $1.51B | $1.76B | $1.61B | $1.37B | $1.04B |
| Gross Profit | $2.86B | $2.74B | $2.97B | $3.15B | $2.20B |
| Gross Profit Ratio | 65.44% | 60.92% | 64.83% | 69.69% | 68.01% |
| Research and Development Expenses | $1.17B | $1.35B | $1.32B | $1.19B | $682.00M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.09B | $1.61B | $1.30B | $2.09B | $941.00M |
| Other Expenses | $1.43B | $847.00M | $-157.00M | $1.01B | $276.00M |
| Operating Expenses | $3.69B | $4.01B | $2.62B | $3.28B | $1.62B |
| Cost and Expenses | $3.77B | $5.57B | $4.23B | $4.65B | $2.66B |
| Interest Income | $46.00M | $58.00M | $11.00M | $61.00M | $41.00M |
| Interest Expense | $100.00M | $77.00M | $26.00M | $61.00M | $49.00M |
| Depreciation and Amortization | $354.00M | $432.00M | $394.00M | $251.00M | $187.00M |
| EBITDA | $-725.00M | $-608.00M | $-3.92B | $747.00M | $767.00M |
| EBITDA Ratio | -16.58% | -13.50% | -85.43% | 16.50% | 23.68% |
| Operating Income | $-833.00M | $-1.07B | $-4.18B | $-123.00M | $580.00M |
| Operating Income Ratio | -19.05% | -23.73% | -91.16% | -2.72% | 17.91% |
| Total Other Income Expenses Net | $-346.00M | $-48.00M | $-157.00M | $1.01B | $276.00M |
| Income Before Tax | $-1.18B | $-1.12B | $-4.34B | $884.00M | $856.00M |
| Income Before Tax Ratio | -26.97% | -24.80% | -94.59% | 19.53% | 26.43% |
| Income Tax Expense | $44.00M | $44.00M | $68.00M | $122.00M | $200.00M |
| Net Income | $-1.22B | $-1.16B | $-4.40B | $762.00M | $656.00M |
| Net Income Ratio | -27.97% | -25.78% | -96.07% | 16.84% | 20.25% |
| EPS | $-7.69 | $-7.35 | $-28.05 | $5.08 | $4.46 |
| EPS Diluted | $-7.69 | $-7.35 | $-28.05 | $5.05 | $4.43 |
| Weighted Average Shares Outstanding | 159.00M | 158.00M | 157.00M | 150.00M | 147.00M |
| Weighted Average Shares Outstanding Diluted | 159.00M | 158.00M | 157.00M | 151.00M | 148.00M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 30, 2025 | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | July 03, 2022 | April 03, 2022 | January 02, 2022 | October 03, 2021 | July 04, 2021 | April 04, 2021 | January 03, 2021 | September 27, 2020 | June 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.04B | $1.10B | $1.08B | $1.11B | $1.08B | $1.12B | $1.12B | $1.18B | $1.09B | $1.08B | $1.11B | $1.16B | $1.22B | $1.20B | $1.11B | $1.13B | $1.09B | $953.00M | $794.00M | $633.00M |
| Cost of Revenue | $358.00M | $376.00M | $335.00M | $391.00M | $409.00M | $447.00M | $435.00M | $444.00M | $432.00M | $363.00M | $398.00M | $395.00M | $408.00M | $381.00M | $338.00M | $324.00M | $329.00M | $323.00M | $268.00M | $205.00M |
| Gross Profit | $683.00M | $728.00M | $745.00M | $721.00M | $667.00M | $675.00M | $684.00M | $732.00M | $655.00M | $720.00M | $717.00M | $767.00M | $815.00M | $817.00M | $770.00M | $802.00M | $764.00M | $630.00M | $526.00M | $428.00M |
| Gross Profit Ratio | 65.61% | 65.94% | 68.98% | 64.84% | 61.99% | 60.16% | 61.13% | 62.24% | 60.26% | 66.48% | 64.30% | 66.01% | 66.64% | 68.20% | 69.49% | 71.23% | 69.90% | 66.11% | 66.25% | 67.61% |
| Research and Development Expenses | $252.00M | $253.00M | $253.00M | $325.00M | $338.00M | $329.00M | $315.00M | $358.00M | $341.00M | $346.00M | $325.00M | $327.00M | $323.00M | $350.00M | $436.00M | $202.00M | $197.00M | $199.00M | $172.00M | $155.00M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $267.00M | $279.00M | $239.00M | $-88.00M | $388.00M | $403.00M | $303.00M | $450.00M | $378.00M | $519.00M | $146.00M | $410.00M | $308.00M | $426.00M | $879.00M | $413.00M | $374.00M | $298.00M | $192.00M | $177.00M |
| Other Expenses | $- | $18.00M | $- | $-332.00M | $8.00M | $34.00M | $-28.00M | $-1.00M | $-14.00M | $-18.00M | $-15.00M | $-53.00M | $-38.00M | $45.00M | $965.00M | $20.00M | $-24.00M | $- | $53.00M | $69.00M |
| Operating Expenses | $519.00M | $553.00M | $492.00M | $237.00M | $726.00M | $732.00M | $618.00M | $808.00M | $719.00M | $847.00M | $471.00M | $737.00M | $631.00M | $776.00M | $1.31B | $615.00M | $571.00M | $497.00M | $364.00M | $332.00M |
| Cost and Expenses | $877.00M | $911.00M | $827.00M | $628.00M | $1.14B | $1.18B | $1.05B | $1.25B | $1.15B | $1.21B | $869.00M | $1.13B | $1.04B | $1.16B | $1.65B | $939.00M | $900.00M | $820.00M | $632.00M | $537.00M |
| Interest Income | $11.00M | $10.00M | $11.00M | $13.00M | $12.00M | $11.00M | $13.00M | $17.00M | $17.00M | $- | $3.00M | $1.00M | $- | $- | $- | $- | $1.00M | $15.00M | $5.00M | $7.00M |
| Interest Expense | $25.00M | $25.00M | $36.00M | $20.00M | $18.00M | $18.00M | $19.00M | $19.00M | $14.00M | $- | $6.00M | $6.00M | $6.00M | $13.00M | $14.00M | $16.00M | $19.00M | $16.00M | $11.00M | $11.00M |
| Depreciation and Amortization | $69.00M | $71.00M | $70.00M | $105.00M | $108.00M | $107.00M | $108.00M | $108.00M | $107.00M | $106.00M | $103.00M | $94.00M | $91.00M | $89.00M | $65.00M | $49.00M | $48.00M | $50.00M | $47.00M | $46.00M |
| EBITDA | $276.00M | $284.00M | $826.00M | $-1.85B | $17.00M | $-43.00M | $-655.00M | $38.00M | $49.00M | $25.00M | $-3.56B | $-537.00M | $237.00M | $52.00M | $170.00M | $236.00M | $241.00M | $365.00M | $209.00M | $142.00M |
| EBITDA Ratio | 26.51% | 25.72% | 76.48% | -166.46% | 1.58% | -3.83% | -58.53% | 3.23% | 4.51% | 2.31% | -319.55% | -46.21% | 19.38% | 4.34% | 15.34% | 20.96% | 22.05% | 38.30% | 26.32% | 22.43% |
| Operating Income | $164.00M | $175.00M | $741.00M | $484.00M | $-59.00M | $-57.00M | $-754.00M | $-88.00M | $-64.00M | $-127.00M | $-3.66B | $-579.00M | $184.00M | $41.00M | $-545.00M | $187.00M | $193.00M | $133.00M | $162.00M | $96.00M |
| Operating Income Ratio | 15.75% | 15.85% | 68.61% | 43.53% | -5.48% | -5.08% | -67.38% | -7.48% | -5.89% | -11.73% | -327.98% | -49.83% | 15.04% | 3.42% | -49.19% | 16.61% | 17.66% | 13.96% | 20.40% | 15.17% |
| Total Other Income Expenses Net | $18.00M | $13.00M | $-21.00M | $-339.00M | $2.00M | $-4.00M | $-28.00M | $-1.00M | $-14.00M | $-41.00M | $-15.00M | $-58.00M | $-44.00M | $45.00M | $965.00M | $20.00M | $-24.00M | $166.00M | $53.00M | $69.00M |
| Income Before Tax | $182.00M | $188.00M | $720.00M | $-1.98B | $-109.00M | $-168.00M | $-782.00M | $-89.00M | $-78.00M | $-168.00M | $-3.67B | $-637.00M | $140.00M | $86.00M | $420.00M | $207.00M | $169.00M | $299.00M | $215.00M | $165.00M |
| Income Before Tax Ratio | 17.48% | 17.03% | 66.67% | -177.70% | -10.13% | -14.97% | -69.88% | -7.57% | -7.18% | -15.51% | -329.33% | -54.82% | 11.45% | 7.18% | 37.91% | 18.38% | 15.46% | 31.37% | 27.08% | 26.07% |
| Income Tax Expense | $51.00M | $1.00M | $15.00M | $12.00M | $17.00M | $8.00M | $-28.00M | $145.00M | $-81.00M | $29.00M | $144.00M | $-102.00M | $54.00M | $-26.00M | $103.00M | $22.00M | $22.00M | $42.00M | $36.00M | $118.00M |
| Net Income | $131.00M | $187.00M | $705.00M | $-1.99B | $-126.00M | $-176.00M | $-754.00M | $-234.00M | $3.00M | $-139.00M | $-3.82B | $-535.00M | $86.00M | $112.00M | $317.00M | $185.00M | $147.00M | $257.00M | $179.00M | $47.00M |
| Net Income Ratio | 12.58% | 16.94% | 65.28% | -178.78% | -11.71% | -15.69% | -67.38% | -19.90% | 0.28% | -12.83% | -342.24% | -46.04% | 7.03% | 9.35% | 28.61% | 16.43% | 13.45% | 26.97% | 22.54% | 7.42% |
| EPS | $0.83 | $1.18 | $4.43 | $-12.50 | $-0.79 | $-1.11 | $-4.77 | $-1.48 | $0.02 | $-0.88 | $-24.31 | $-3.41 | $0.55 | $0.71 | $2.09 | $1.27 | $1.01 | $1.76 | $1.23 | $0.32 |
| EPS Diluted | $0.82 | $1.17 | $4.41 | $-12.50 | $-0.79 | $-1.11 | $-4.77 | $-1.48 | $0.02 | $-0.88 | $-24.31 | $-3.41 | $0.54 | $0.71 | $2.07 | $1.26 | $1.00 | $1.75 | $1.21 | $0.32 |
| Weighted Average Shares Outstanding | 159.00M | 159.00M | 159.00M | 159.00M | 159.00M | 159.00M | 158.00M | 158.00M | 158.00M | 158.00M | 157.00M | 157.00M | 157.00M | 157.00M | 152.00M | 146.00M | 146.00M | 146.00M | 146.00M | 147.00M |
| Weighted Average Shares Outstanding Diluted | 159.00M | 160.00M | 160.00M | 159.00M | 159.00M | 159.00M | 158.00M | 158.00M | 158.00M | 158.00M | 157.00M | 157.00M | 159.00M | 157.00M | 153.00M | 147.00M | 147.00M | 147.00M | 148.00M | 148.00M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 29, 2024 | December 31, 2023 | January 01, 2023 | January 02, 2022 | January 03, 2021 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.13B | $1.05B | $2.01B | $1.23B | $1.81B |
| Short Term Investments | $93.00M | $6.00M | $26.00M | $107.00M | $1.66B |
| Cash and Short Term Investments | $1.22B | $1.05B | $2.04B | $1.34B | $3.47B |
| Net Receivables | $735.00M | $752.00M | $688.00M | $648.00M | $487.00M |
| Inventory | $547.00M | $587.00M | $568.00M | $431.00M | $372.00M |
| Other Current Assets | $244.00M | $216.00M | $536.00M | $295.00M | $290.00M |
| Total Current Assets | $2.75B | $2.61B | $3.56B | $2.71B | $4.48B |
| Property Plant Equipment Net | $1.23B | $1.55B | $1.74B | $1.70B | $1.45B |
| Goodwill | $1.11B | $2.54B | $3.24B | $7.11B | $897.00M |
| Intangible Assets | $295.00M | $2.99B | $3.29B | $3.25B | $142.00M |
| Goodwill and Intangible Assets | $1.41B | $5.54B | $6.52B | $10.36B | $1.04B |
| Long Term Investments | $- | $196.00M | $211.00M | $213.00M | $418.00M |
| Tax Assets | $567.00M | $- | $-211.00M | $-213.00M | $20.00M |
| Other Non-Current Assets | $348.00M | $217.00M | $423.00M | $445.00M | $171.00M |
| Total Non-Current Assets | $3.56B | $7.50B | $8.69B | $12.50B | $3.10B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $6.30B | $10.11B | $12.25B | $15.22B | $7.58B |
| Account Payables | $221.00M | $245.00M | $293.00M | $332.00M | $192.00M |
| Short Term Debt | $578.00M | $86.00M | $1.32B | $71.00M | $562.00M |
| Tax Payables | $101.00M | $79.00M | $97.00M | $98.00M | $68.00M |
| Deferred Revenue | $- | $252.00M | $245.00M | $234.00M | $186.00M |
| Other Current Liabilities | $726.00M | $908.00M | $814.00M | $358.00M | $236.00M |
| Total Current Liabilities | $1.55B | $1.57B | $2.77B | $1.09B | $1.24B |
| Long Term Debt | $2.04B | $2.18B | $2.23B | $2.47B | $1.34B |
| Deferred Revenue Non-Current | $- | $- | $63.00M | $63.00M | $44.00M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-63.00M | $-63.00M | $-44.00M |
| Other Non-Current Liabilities | $893.00M | $620.00M | $649.00M | $915.00M | $303.00M |
| Total Non-Current Liabilities | $2.38B | $2.80B | $2.88B | $3.38B | $1.65B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $3.93B | $4.37B | $5.65B | $4.48B | $2.89B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M |
| Retained Earnings | $-1.24B | $-19.00M | $1.14B | $5.49B | $4.72B |
| Accumulated Other Comprehensive Income Loss | $22.00M | $-1.00M | $3.00M | $17.00M | $2.00M |
| Other Total Stockholders Equity | $3.59B | $5.76B | $5.45B | $5.24B | $-33.00M |
| Total Stockholders Equity | $2.37B | $5.75B | $6.60B | $10.74B | $4.69B |
| Total Equity | $2.37B | $5.75B | $6.60B | $10.74B | $4.69B |
| Total Liabilities and Stockholders Equity | $6.30B | $10.11B | $12.25B | $15.22B | $7.58B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $6.30B | $10.11B | $12.25B | $15.22B | $7.58B |
| Total Investments | $93.00M | $202.00M | $26.00M | $107.00M | $1.66B |
| Total Debt | $2.62B | $2.26B | $3.48B | $2.47B | $1.85B |
| Net Debt | $1.50B | $1.21B | $1.47B | $1.24B | $45.00M |
Balance Sheet Charts
| Breakdown | March 30, 2025 | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | July 03, 2022 | April 03, 2022 | January 02, 2022 | October 03, 2021 | July 04, 2021 | April 04, 2021 | January 03, 2021 | September 27, 2020 | June 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.11B | $1.13B | $869.00M | $920.00M | $1.11B | $1.05B | $927.00M | $1.55B | $1.49B | $2.01B | $1.00B | $1.29B | $1.35B | $1.23B | $1.08B | $4.20B | $4.43B | $1.81B | $1.76B | $1.77B |
| Short Term Investments | $124.00M | $93.00M | $70.00M | $74.00M | $7.00M | $6.00M | $6.00M | $6.00M | $24.00M | $26.00M | $41.00M | $38.00M | $65.00M | $107.00M | $185.00M | $90.00M | $197.00M | $1.66B | $1.56B | $1.50B |
| Cash and Short Term Investments | $1.24B | $1.22B | $939.00M | $994.00M | $1.11B | $1.05B | $933.00M | $1.56B | $1.52B | $2.04B | $1.04B | $1.33B | $1.42B | $1.34B | $1.26B | $4.29B | $4.63B | $3.47B | $3.32B | $3.27B |
| Net Receivables | $699.00M | $735.00M | $699.00M | $657.00M | $650.00M | $752.00M | $690.00M | $741.00M | $665.00M | $688.00M | $628.00M | $642.00M | $614.00M | $648.00M | $604.00M | $540.00M | $517.00M | $487.00M | $464.00M | $385.00M |
| Inventory | $537.00M | $547.00M | $574.00M | $561.00M | $584.00M | $587.00M | $615.00M | $617.00M | $586.00M | $568.00M | $559.00M | $518.00M | $465.00M | $431.00M | $401.00M | $380.00M | $364.00M | $372.00M | $415.00M | $435.00M |
| Other Current Assets | $200.00M | $244.00M | $161.00M | $247.00M | $241.00M | $432.00M | $268.00M | $306.00M | $403.00M | $268.00M | $259.00M | $404.00M | $260.00M | $295.00M | $362.00M | $208.00M | $262.00M | $290.00M | $252.00M | $212.00M |
| Total Current Assets | $2.67B | $2.75B | $2.37B | $2.46B | $2.58B | $2.61B | $2.51B | $3.22B | $3.17B | $3.56B | $2.49B | $2.89B | $2.75B | $2.71B | $2.45B | $5.31B | $5.64B | $4.48B | $4.33B | $4.19B |
| Property Plant Equipment Net | $1.19B | $1.23B | $1.28B | $1.32B | $1.51B | $1.55B | $1.62B | $1.71B | $1.74B | $1.74B | $1.75B | $1.75B | $1.74B | $1.70B | $1.69B | $1.48B | $1.44B | $1.45B | $1.46B | $1.44B |
| Goodwill | $1.11B | $1.11B | $1.11B | $1.08B | $2.54B | $2.54B | $2.53B | $3.24B | $3.24B | $3.24B | $3.24B | $7.16B | $7.11B | $7.11B | $7.10B | $966.00M | $897.00M | $897.00M | $897.00M | $894.00M |
| Intangible Assets | $278.00M | $295.00M | $305.00M | $278.00M | $2.94B | $2.99B | $3.03B | $3.19B | $3.24B | $2.58B | $3.33B | $3.20B | $3.21B | $3.25B | $3.35B | $162.00M | $134.00M | $142.00M | $149.00M | $156.00M |
| Goodwill and Intangible Assets | $1.39B | $1.41B | $1.42B | $1.36B | $5.49B | $5.54B | $5.56B | $6.43B | $6.48B | $5.82B | $6.57B | $10.36B | $10.32B | $10.36B | $10.45B | $1.13B | $1.03B | $1.04B | $1.05B | $1.05B |
| Long Term Investments | $- | $- | $- | $217.00M | $213.00M | $196.00M | $193.00M | $205.00M | $200.00M | $211.00M | $226.00M | $229.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $553.00M | $567.00M | $617.00M | $632.00M | $- | $- | $-193.00M | $-205.00M | $-200.00M | $- | $-226.00M | $-229.00M | $- | $- | $- | $- | $- | $20.00M | $19.00M | $13.00M |
| Other Non-Current Assets | $373.00M | $348.00M | $321.00M | $97.00M | $245.00M | $217.00M | $439.00M | $417.00M | $423.00M | $917.00M | $448.00M | $449.00M | $457.00M | $445.00M | $478.00M | $756.00M | $638.00M | $589.00M | $555.00M | $552.00M |
| Total Non-Current Assets | $3.51B | $3.56B | $3.64B | $3.62B | $7.46B | $7.50B | $7.62B | $8.55B | $8.64B | $8.69B | $8.77B | $12.56B | $12.52B | $12.50B | $12.61B | $3.37B | $3.11B | $3.10B | $3.08B | $3.05B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $6.18B | $6.30B | $6.01B | $6.08B | $10.04B | $10.11B | $10.12B | $11.77B | $11.81B | $12.25B | $11.26B | $15.45B | $15.27B | $15.22B | $15.06B | $8.68B | $8.76B | $7.58B | $7.40B | $7.25B |
| Account Payables | $207.00M | $221.00M | $191.00M | $199.00M | $201.00M | $245.00M | $240.00M | $244.00M | $242.00M | $293.00M | $281.00M | $282.00M | $291.00M | $332.00M | $248.00M | $200.00M | $178.00M | $192.00M | $156.00M | $135.00M |
| Short Term Debt | $577.00M | $578.00M | $73.00M | $815.00M | $86.00M | $86.00M | $85.00M | $834.00M | $828.00M | $1.32B | $1.32B | $1.32B | $571.00M | $71.00M | $66.00M | $53.00M | $541.00M | $562.00M | $561.00M | $551.00M |
| Tax Payables | $80.00M | $101.00M | $127.00M | $177.00M | $67.00M | $79.00M | $65.00M | $84.00M | $74.00M | $- | $81.00M | $81.00M | $91.00M | $98.00M | $77.00M | $127.00M | $116.00M | $68.00M | $46.00M | $44.00M |
| Deferred Revenue | $256.00M | $- | $235.00M | $238.00M | $248.00M | $252.00M | $242.00M | $-750.00M | $258.00M | $- | $225.00M | $226.00M | $232.00M | $234.00M | $198.00M | $182.00M | $188.00M | $186.00M | $154.00M | $153.00M |
| Other Current Liabilities | $320.00M | $726.00M | $349.00M | $779.00M | $872.00M | $908.00M | $850.00M | $1.14B | $828.00M | $1.16B | $759.00M | $972.00M | $305.00M | $358.00M | $325.00M | $312.00M | $245.00M | $236.00M | $198.00M | $232.00M |
| Total Current Liabilities | $1.44B | $1.55B | $975.00M | $2.21B | $1.47B | $1.57B | $1.48B | $2.30B | $2.23B | $2.77B | $2.67B | $2.88B | $1.49B | $1.09B | $914.00M | $874.00M | $1.27B | $1.24B | $1.11B | $1.11B |
| Long Term Debt | $2.03B | $2.04B | $2.60B | $2.11B | $2.19B | $2.18B | $2.19B | $2.21B | $2.23B | $2.23B | $1.24B | $1.27B | $2.04B | $2.47B | $2.47B | $2.38B | $2.34B | $1.34B | $1.34B | $1.34B |
| Deferred Revenue Non-Current | $- | $- | $- | $67.00M | $76.00M | $77.00M | $73.00M | $73.00M | $66.00M | $- | $63.00M | $65.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $616.00M | $700.00M | $687.00M | $-73.00M | $-73.00M | $-66.00M | $- | $-63.00M | $-65.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $344.00M | $893.00M | $313.00M | $331.00M | $566.00M | $620.00M | $555.00M | $702.00M | $654.00M | $649.00M | $613.00M | $853.00M | $845.00M | $915.00M | $1.08B | $238.00M | $229.00M | $303.00M | $245.00M | $230.00M |
| Total Non-Current Liabilities | $2.37B | $2.38B | $2.91B | $2.44B | $2.83B | $2.80B | $2.74B | $2.92B | $2.89B | $2.88B | $1.86B | $2.12B | $2.89B | $3.38B | $3.56B | $2.62B | $2.56B | $1.65B | $1.59B | $1.57B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $3.81B | $3.93B | $3.89B | $4.64B | $4.31B | $4.37B | $4.22B | $5.22B | $5.12B | $5.65B | $4.53B | $5.00B | $4.38B | $4.48B | $4.47B | $3.50B | $3.83B | $2.89B | $2.70B | $2.69B |
| Preferred Stock | $- | $- | $- | $- | $131.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M |
| Retained Earnings | $-1.11B | $-1.24B | $-1.43B | $-2.13B | $-145.00M | $-19.00M | $157.00M | $911.00M | $1.08B | $1.14B | $1.28B | $5.10B | $5.63B | $5.49B | $5.37B | $5.05B | $4.87B | $4.72B | $4.47B | $4.29B |
| Accumulated Other Comprehensive Income Loss | $8.00M | $22.00M | $-5.00M | $14.00M | $12.00M | $-1.00M | $21.00M | $12.00M | $-1.00M | $3.00M | $39.00M | $30.00M | $18.00M | $17.00M | $13.00M | $8.00M | $8.00M | $2.00M | $12.00M | $14.00M |
| Other Total Stockholders Equity | $3.47B | $3.59B | $3.56B | $3.55B | $5.87B | $5.76B | $5.72B | $5.63B | $5.55B | $5.45B | $5.41B | $5.32B | $5.24B | $5.24B | $5.21B | $115.00M | $42.00M | $-33.00M | $220.00M | $260.00M |
| Total Stockholders Equity | $2.37B | $2.37B | $2.12B | $1.44B | $5.73B | $5.75B | $5.90B | $6.55B | $6.69B | $6.60B | $6.73B | $10.44B | $10.89B | $10.74B | $10.59B | $5.18B | $4.92B | $4.69B | $4.70B | $4.56B |
| Total Equity | $2.37B | $2.37B | $2.12B | $1.44B | $5.73B | $5.75B | $5.90B | $6.55B | $6.69B | $6.60B | $6.73B | $10.44B | $10.89B | $10.74B | $10.59B | $5.18B | $4.92B | $4.69B | $4.70B | $4.56B |
| Total Liabilities and Stockholders Equity | $6.18B | $6.30B | $6.01B | $6.08B | $10.04B | $10.11B | $10.12B | $11.77B | $11.81B | $12.25B | $11.26B | $15.45B | $15.27B | $15.22B | $15.06B | $8.68B | $8.76B | $7.58B | $7.40B | $7.25B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $6.18B | $6.30B | $6.01B | $6.08B | $10.04B | $10.11B | $10.12B | $11.77B | $11.81B | $12.25B | $11.26B | $15.45B | $15.27B | $15.22B | $15.06B | $8.68B | $8.76B | $7.58B | $7.40B | $7.25B |
| Total Investments | $124.00M | $93.00M | $70.00M | $291.00M | $220.00M | $202.00M | $6.00M | $6.00M | $24.00M | $237.00M | $41.00M | $38.00M | $65.00M | $107.00M | $185.00M | $90.00M | $197.00M | $1.66B | $1.56B | $1.50B |
| Total Debt | $2.61B | $2.62B | $2.67B | $2.92B | $2.28B | $2.26B | $2.19B | $2.96B | $2.98B | $3.56B | $2.49B | $2.59B | $2.62B | $2.47B | $2.47B | $2.38B | $2.82B | $1.85B | $1.85B | $1.84B |
| Net Debt | $1.49B | $1.50B | $1.80B | $2.00B | $1.17B | $1.21B | $1.26B | $1.41B | $1.49B | $1.54B | $1.49B | $1.30B | $1.26B | $1.24B | $1.39B | $-1.81B | $-1.61B | $45.00M | $90.00M | $73.00M |
Annual Cash Flow
| Breakdown | December 29, 2024 | December 31, 2023 | January 01, 2023 | January 02, 2022 | January 03, 2021 |
|---|---|---|---|---|---|
| Net Income | $-1.22B | $-1.16B | $-4.40B | $762.00M | $656.00M |
| Depreciation and Amortization | $354.00M | $432.00M | $394.00M | $251.00M | $187.00M |
| Deferred Income Tax | $-112.00M | $-33.00M | $-23.00M | $-76.00M | $117.00M |
| Stock Based Compensation | $370.00M | $380.00M | $366.00M | $754.00M | $194.00M |
| Change in Working Capital | $-483.00M | $-90.00M | $204.00M | $-152.00M | $73.00M |
| Accounts Receivables | $- | $-40.00M | $-12.00M | $-164.00M | $89.00M |
| Inventory | $19.00M | $-20.00M | $-135.00M | $-58.00M | $-12.00M |
| Accounts Payables | $-4.00M | $-44.00M | $-38.00M | $60.00M | $40.00M |
| Other Working Capital | $-479.00M | $14.00M | $389.00M | $10.00M | $-44.00M |
| Other Non Cash Items | $1.93B | $950.00M | $3.85B | $-994.00M | $-147.00M |
| Net Cash Provided by Operating Activities | $837.00M | $478.00M | $392.00M | $545.00M | $1.08B |
| Investments in Property Plant and Equipment | $-128.00M | $-195.00M | $-466.00M | $-208.00M | $-189.00M |
| Acquisitions Net | $- | $-29.00M | $-85.00M | $-2.44B | $-98.00M |
| Purchases of Investments | $-52.00M | $-6.00M | $-40.00M | $-129.00M | $-1.93B |
| Sales Maturities of Investments | $- | $- | $180.00M | $1.71B | $1.79B |
| Other Investing Activities | $2.00M | $-1.00M | $-180.00M | $1.58B | $-132.00M |
| Net Cash Used for Investing Activities | $-178.00M | $-231.00M | $-591.00M | $-1.07B | $-554.00M |
| Debt Repayment | $491.00M | $-1.24B | $991.00M | $471.00M | $- |
| Common Stock Issued | $56.00M | $67.00M | $63.00M | $60.00M | $61.00M |
| Common Stock Repurchased | $-116.00M | $- | $- | $- | $-736.00M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-1.00B | $-42.00M | $-54.00M | $-582.00M | $-91.00M |
| Net Cash Used Provided by Financing Activities | $-570.00M | $-1.21B | $1.00B | $-51.00M | $-766.00M |
| Effect of Forex Changes on Cash | $-10.00M | $- | $-22.00M | $-3.00M | $8.00M |
| Net Change in Cash | $79.00M | $-963.00M | $779.00M | $-578.00M | $-232.00M |
| Cash at End of Period | $1.13B | $1.05B | $2.01B | $1.23B | $1.81B |
| Cash at Beginning of Period | $1.05B | $2.01B | $1.23B | $1.81B | $2.04B |
| Operating Cash Flow | $837.00M | $478.00M | $392.00M | $545.00M | $1.08B |
| Capital Expenditure | $-128.00M | $-195.00M | $-466.00M | $-208.00M | $-189.00M |
| Free Cash Flow | $709.00M | $282.00M | $-74.00M | $337.00M | $891.00M |
Cash Flow Charts
| Breakdown | March 30, 2025 | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | July 03, 2022 | April 03, 2022 | January 02, 2022 | October 03, 2021 | July 04, 2021 | April 04, 2021 | January 03, 2021 | September 27, 2020 | June 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $131.00M | $187.00M | $704.00M | $-1.99B | $-126.00M | $-176.00M | $-3.82B | $-449.00M | $3.00M | $-139.00M | $-3.82B | $-535.00M | $86.00M | $112.00M | $317.00M | $186.00M | $147.00M | $257.00M | $179.00M | $47.00M |
| Depreciation and Amortization | $69.00M | $71.00M | $70.00M | $105.00M | $108.00M | $107.00M | $108.00M | $108.00M | $107.00M | $106.00M | $103.00M | $94.00M | $91.00M | $89.00M | $65.00M | $49.00M | $48.00M | $50.00M | $47.00M | $46.00M |
| Deferred Income Tax | $16.00M | $49.00M | $19.00M | $-156.00M | $-24.00M | $9.00M | $9.00M | $12.00M | $-17.00M | $- | $-6.00M | $-13.00M | $-21.00M | $5.00M | $75.00M | $-77.00M | $-79.00M | $67.00M | $3.00M | $76.00M |
| Stock Based Compensation | $73.00M | $79.00M | $83.00M | $112.00M | $96.00M | $94.00M | $87.00M | $106.00M | $93.00M | $100.00M | $83.00M | $91.00M | $92.00M | $98.00M | $509.00M | $80.00M | $67.00M | $78.00M | $61.00M | $16.00M |
| Change in Working Capital | $-4.00M | $2.00M | $-56.00M | $82.00M | $-26.00M | $78.00M | $1.00M | $26.00M | $10.00M | $-27.00M | $-122.00M | $405.00M | $-65.00M | $15.00M | $-261.00M | $32.00M | $62.00M | $104.00M | $-95.00M | $110.00M |
| Accounts Receivables | $46.00M | $- | $-72.00M | $-18.00M | $90.00M | $-9.00M | $47.00M | $-79.00M | $1.00M | $-25.00M | $12.00M | $-30.00M | $31.00M | $-39.00M | $-64.00M | $-22.00M | $-39.00M | $-19.00M | $-82.00M | $91.00M |
| Inventory | $10.00M | $- | $-4.00M | $- | $4.00M | $27.00M | $2.00M | $-31.00M | $-18.00M | $-8.00M | $-41.00M | $-52.00M | $-34.00M | $-31.00M | $-18.00M | $-17.00M | $8.00M | $44.00M | $19.00M | $-51.00M |
| Accounts Payables | $-15.00M | $-4.00M | $30.00M | $7.00M | $-37.00M | $6.00M | $-6.00M | $2.00M | $-46.00M | $- | $1.00M | $-13.00M | $-39.00M | $88.00M | $-40.00M | $20.00M | $-8.00M | $42.00M | $11.00M | $3.00M |
| Other Working Capital | $-45.00M | $-12.00M | $-10.00M | $93.00M | $-83.00M | $54.00M | $-42.00M | $134.00M | $73.00M | $6.00M | $-94.00M | $500.00M | $-23.00M | $-3.00M | $-139.00M | $51.00M | $101.00M | $37.00M | $-43.00M | $67.00M |
| Other Non Cash Items | $-45.00M | $-22.00M | $-504.00M | $2.26B | $304.00M | $111.00M | $3.75B | $302.00M | $-186.00M | $107.00M | $3.71B | $83.00M | $-11.00M | $-37.00M | $-977.00M | $-17.00M | $37.00M | $-150.00M | $-42.00M | $-55.00M |
| Net Cash Provided by Operating Activities | $240.00M | $364.00M | $316.00M | $80.00M | $77.00M | $223.00M | $139.00M | $105.00M | $10.00M | $147.00M | $-52.00M | $125.00M | $172.00M | $282.00M | $-272.00M | $253.00M | $282.00M | $406.00M | $153.00M | $240.00M |
| Investments in Property Plant and Equipment | $-32.00M | $-29.00M | $-32.00M | $-31.00M | $-36.00M | $-51.00M | $-45.00M | $-47.00M | $-52.00M | $-88.00M | $-246.00M | $-71.00M | $-61.00M | $-70.00M | $-52.00M | $-44.00M | $-42.00M | $-62.00M | $-48.00M | $-39.00M |
| Acquisitions Net | $- | $- | $-81.00M | $- | $- | $-29.00M | $- | $-18.00M | $- | $- | $- | $-85.00M | $- | $-938.00M | $-2.36B | $-132.00M | $52.00M | $- | $-3.00M | $-95.00M |
| Purchases of Investments | $-24.00M | $-19.00M | $-11.00M | $-10.00M | $-12.00M | $13.00M | $-8.00M | $-8.00M | $-3.00M | $- | $-4.00M | $-9.00M | $-13.00M | $-8.00M | $-32.00M | $-9.00M | $-80.00M | $-1.06B | $-215.00M | $-398.00M |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $-18.00M | $- | $18.00M | $- | $- | $- | $85.00M | $- | $78.00M | $2.40B | $188.00M | $1.45B | $1.08B | $201.00M | $212.00M |
| Other Investing Activities | $-7.00M | $- | $83.00M | $-9.00M | $-48.00M | $-5.00M | $-1.00M | $18.00M | $-1.00M | $-14.00M | $-184.00M | $-85.00M | $- | $358.00M | $-2.40B | $- | $- | $1.00M | $- | $- |
| Net Cash Used for Investing Activities | $-63.00M | $-48.00M | $-41.00M | $-41.00M | $-48.00M | $-85.00M | $-54.00M | $-37.00M | $-56.00M | $-102.00M | $-250.00M | $-165.00M | $-74.00M | $-580.00M | $-2.45B | $3.00M | $1.38B | $-33.00M | $-65.00M | $-320.00M |
| Debt Repayment | $- | $1.24B | $-253.00M | $744.00M | $- | $- | $-734.00M | $- | $-500.00M | $- | $- | $- | $- | $- | $- | $-490.00M | $961.00M | $- | $- | $- |
| Common Stock Issued | $27.00M | $- | $20.00M | $- | $36.00M | $- | $30.00M | $- | $37.00M | $- | $30.00M | $- | $33.00M | $1.00M | $28.00M | $- | $31.00M | $- | $27.00M | $2.00M |
| Common Stock Repurchased | $-200.00M | $-17.00M | $-99.00M | $-1.00M | $- | $-26.00M | $- | $-3.00M | $- | $-35.00M | $- | $-5.00M | $- | $- | $- | $- | $- | $-281.00M | $-125.00M | $-142.00M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-22.00M | $-1.27B | $- | $-970.00M | $-1.00M | $-27.00M | $-3.00M | $-3.00M | $-10.00M | $991.00M | $-2.00M | $-5.00M | $-12.00M | $-130.00M | $-422.00M | $-6.00M | $-24.00M | $-50.00M | $-3.00M | $-3.00M |
| Net Cash Used Provided by Financing Activities | $-195.00M | $-47.00M | $-332.00M | $-226.00M | $35.00M | $-26.00M | $-707.00M | $-3.00M | $-473.00M | $956.00M | $28.00M | $-5.00M | $21.00M | $-129.00M | $-394.00M | $-496.00M | $968.00M | $-331.00M | $-101.00M | $-143.00M |
| Effect of Forex Changes on Cash | $4.00M | $-11.00M | $6.00M | $-1.00M | $-4.00M | $9.00M | $-4.00M | $-6.00M | $2.00M | $10.00M | $-15.00M | $-17.00M | $- | $-1.00M | $-2.00M | $3.00M | $-3.00M | $7.00M | $4.00M | $2.00M |
| Net Change in Cash | $-14.00M | $258.00M | $-51.00M | $-188.00M | $60.00M | $121.00M | $-626.00M | $59.00M | $-517.00M | $1.01B | $-289.00M | $-62.00M | $119.00M | $152.00M | $-3.12B | $-237.00M | $2.62B | $49.00M | $-9.00M | $-221.00M |
| Cash at End of Period | $1.11B | $1.13B | $869.00M | $920.00M | $1.11B | $1.05B | $927.00M | $1.55B | $1.49B | $2.01B | $1.00B | $1.29B | $1.35B | $1.23B | $1.08B | $4.20B | $4.43B | $1.81B | $1.76B | $1.77B |
| Cash at Beginning of Period | $1.13B | $869.00M | $920.00M | $1.11B | $1.05B | $927.00M | $1.55B | $1.49B | $2.01B | $1.00B | $1.29B | $1.35B | $1.23B | $1.08B | $4.20B | $4.43B | $1.81B | $1.76B | $1.77B | $1.99B |
| Operating Cash Flow | $240.00M | $364.00M | $316.00M | $80.00M | $77.00M | $223.00M | $139.00M | $105.00M | $10.00M | $147.00M | $-52.00M | $125.00M | $172.00M | $282.00M | $-272.00M | $253.00M | $282.00M | $406.00M | $153.00M | $240.00M |
| Capital Expenditure | $-39.00M | $-29.00M | $-32.00M | $-31.00M | $-36.00M | $-51.00M | $-45.00M | $-47.00M | $-52.00M | $-88.00M | $-246.00M | $-71.00M | $-61.00M | $-70.00M | $-52.00M | $-44.00M | $-42.00M | $-62.00M | $-48.00M | $-39.00M |
| Free Cash Flow | $201.00M | $335.00M | $284.00M | $49.00M | $41.00M | $172.00M | $94.00M | $58.00M | $-42.00M | $59.00M | $-298.00M | $54.00M | $111.00M | $212.00M | $-324.00M | $209.00M | $240.00M | $344.00M | $105.00M | $201.00M |
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
$80.30
Stock Price
$12.71B
Market Cap
8.97K
Employees
San Diego, CA
Location
Revenue (FY 2024)
$4.37B
-2.9% YoY
Net Income (FY 2024)
$-1.22B
-5.3% YoY
EPS (FY 2024)
$-7.69
-4.6% YoY
Free Cash Flow (FY 2024)
$709.00M
151.4% YoY
Profitability
Gross Margin
65.4%
Net Margin
-28.0%
ROE
-51.5%
ROA
-19.4%
Valuation
P/E Ratio
-17.37
P/S Ratio
4.86
EV/EBITDA
-31.36
Market Cap
$12.71B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$837.00M
75.1% YoY
Free Cash Flow
$709.00M
151.4% YoY
Balance Sheet Summary
Total Assets
$6.30B
-37.7% YoY
Total Debt
$2.62B
15.9% YoY
Shareholder Equity
$2.37B
-59.0% YoY
Dividend Overview
No Dividend Data
Illumina, Inc. doesn't currently pay dividends.
Illumina Dividends
Explore Illumina's dividend history, including dividend yield, payout ratio, and historical payments.
Illumina News
Read the latest news about Illumina, including recent articles, headlines, and updates.
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO , May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays.
Illumina: Multiple Headwinds Point To Limited Upside In 2025
Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in line, but updated guidance predicts a revenue decline of 1%-3%, due to China headwinds and uncertain U.S. research funding. Despite a $100 million cost reduction program and ongoing R&D investments, Illumina's stock appears overvalued by nearly 18% based on a DCF analysis.
Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Blanchett - Interim Head of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Dave Westenberg - Piper Sandler Jack Meehan - Nephron Vijay Kumar - Evercore Tycho Peterson - Jefferies Conor McNamara - RBC Capital Markets Mike Ryskin - Bank of America Kyle Mikson - Canaccord Operator Good day ladies and gentlemen, and welcome to the First Quarter 2025 Illumina Earnings Conference Call. At this time, all participants are in a listen only mode.
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO , May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development.
Resmed Names Salli Schwartz as Chief Investor Relations Officer
Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community
Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Illumina price target lowered to $85 from $90 at Citi
Citi lowered the firm's price target on Illumina to $85 from $90 and keeps a Neutral rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes tariffs and the National Institutes of Health spending cuts are overhands on the sector.
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years.
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
Stephen MacMillan to retire from the Board SAN DIEGO , March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board.
Activist investor Keith Meister to join Illumina's board, WSJ reports
Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO , March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical development.
Illumina addresses recent developments in China
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50 SAN DIEGO , March 10, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export sequencing instruments into China. Illumina respects MOFCOM's decision and will continue to comply with all applicable laws and regulations wherever the company operates.
Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year
Illumina leads as highest-scoring U.S. company in its industry SAN DIEGO , March 6, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index (formerly part of the Dow Jones Sustainability Indices), and recognized for the fourth year in a row as a Sustainability Yearbook Member. Illumina, which scored in the top 15% of the Best-in-Class World Index, also ranked as the highest-scoring US company in the Life Sciences Tools & Services Sector.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ILMN.